Retracted: Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment Jonathan Pearson-Stuttard, BMBCh, Bin Zhou, MSc, Vasilis Kontis, PhD, James Bentham, PhD, Marc J Gunter, PhD, Prof Majid Ezzati, FMed Sci The Lancet Diabetes & Endocrinology Volume 6, Issue 2, Pages 95-104 (February 2018) DOI: 10.1016/S2213-8587(17)30366-2 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 1 Global cancer cases in 2012 attributable to diabetes and high BMI, individually and combined, in the conservative and independent scenarios, by region BMI=body-mass index. The Lancet Diabetes & Endocrinology 2018 6, 95-104DOI: (10.1016/S2213-8587(17)30366-2) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 2 Global site-specific cancer cases in 2012 Cases by (A) diabetes and high BMI, individually and in combination, in the conservative and independent scenarios and (B) region, in the combined independent scenario. BMI=body-mass index. The Lancet Diabetes & Endocrinology 2018 6, 95-104DOI: (10.1016/S2213-8587(17)30366-2) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 3 Population attributable fraction of all cancer incidence in 2012 Population attributable fractions shown are those of (A) diabetes, (B) high BMI, and (C) diabetes and high BMI combined as independent risks. Countries shown in grey did not have cancer incidence data. BMI=body-mass index. The Lancet Diabetes & Endocrinology 2018 6, 95-104DOI: (10.1016/S2213-8587(17)30366-2) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions